Dataset related to article "prognostic factors and outocome in HER2 + in breast cancer with CNS metastases "
Giovanna Masci(Humanitas University), Armando Santoro(IRCCS Humanitas Research Hospital), Monica Zuradelli(Humanitas University), Giulia Bottai(Humanitas University), Rita De Sanctis(Humanitas University), Elisa Agostinetto(Université Libre de Bruxelles), Laura Giordano(Istituti di Ricovero e Cura a Carattere Scientifico), Agnese Losurdo(Humanitas University), Lorenzo Bello(Institute of Neurological Sciences), Marta Scorsetti(Humanitas University), Rosalba Torrisi(IRCCS Humanitas Research Hospital), Piera Navarria(Fondazione Humanitas per la Ricerca), Fiorenza De Rose
Cited by 0
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646